AXSM vs BBIO Stock Comparison

BBIO currently leads AXSM in this stock comparison, with AIQ scores of 64 vs 47. The clearest difference is momentum, while AXSM has the stronger value profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 17 points
AXSM
Healthcare
vs
BBIO
Healthcare
AXSM
Axsome Therapeutics, Inc.
Price
$142
Day move
-1.86%
AIQ Score
47/100
Best edge
Value
Sector
Healthcare
BBIO
BridgeBio Pharma, Inc.
Leads
Price
$78.30
Day move
+0.17%
AIQ Score
64/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between AXSM and BBIO?

BBIO leads the current stock comparison as BridgeBio Pharma, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Axsome Therapeutics, Inc. vs BridgeBio Pharma, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 6/10

BBIO leads

BBIO leads by 17 AIQ points, primarily on Momentum and Quality, having only recently taken the lead back from AXSM. Wall Street currently favors AXSM on target upside.

Fragile: 3 of 6 evidence groups support BBIO, the lead recently changed hands, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Reversed
AXSM

Axsome Therapeutics, Inc.

AIQ Score
47/100
AIQ Edge Score
3/10
BBIO

BridgeBio Pharma, Inc.

Leads
AIQ Score
64/100
AIQ Edge Score
7/10

The Algovestiq AIQ Score currently favors BBIO over AXSM, 64 versus 47 as of Nov 15, 2026. BBIO's advantage is driven primarily by stronger momentum and quality, while AXSM holds the stronger value profile. BBIO also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors AXSM. 3 of 6 covered evidence groups favor BBIO today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. BBIO lead: Reversed — AXSM led by 1 AIQ points 30 sessions ago; BBIO now leads by 17.

Compare Axsome Therapeutics, Inc. and BridgeBio Pharma, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

AXSM
+310.1%
BBIO
+69.8%

Price return comparison

Growth of $10,000, price only

AXSM $41,010 · BBIO $16,985

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare AXSM and BBIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

AXSM advantage
0
BBIO advantage
  • Momentum24 vs 69
    BBIO +45
  • Value65 vs 55
    AXSM +10
  • Quality57 vs 66
    BBIO +9
  • Risk Resilience57 vs 62
    BBIO +5

3 of 6 evidence groups favor BBIO. BBIO’s edge is concentrated in momentum and quality; AXSM keeps a meaningful value edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

AXSM0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 4 active signals are unchanged.

BBIO+1 AIQ

Largest factor move: Quality +1

No signal started or stopped since the prior session; its 5 active signals are unchanged.

BBIO's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — AXSM and BBIO both carry a full feed there.

The central trade-off

BBIO (BridgeBio Pharma, Inc.): the stronger current systematic profile, led by momentum and quality.

AXSM (Axsome Therapeutics, Inc.): the counter-case, on value, valuation, analyst expectations — but at materially higher volatility, 53.2% against 39.1%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

BBIO

BBIO on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

AXSM

AXSM on combined revenue and EPS growth.

Value

AXSM

AXSM on the peer-relative Value factor, by 10 points.

Momentum

BBIO

BBIO on the Momentum factor, by 45 points.

Lower downside

BBIO

BBIO on Risk Resilience, by 5 points.

Analyst upside

AXSM

AXSM on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors BBIO, analyst targets favor AXSM. That disagreement is the most useful thing on this page.

MeasureAXSMBBIONote
Implied upside to target+83.6%+42%AXSM has more room
Target dispersion+21.9%+62.1%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering2222Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor BBIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreBBIO47 vs 64
FundamentalsEvenrevenue growth 18.9% vs 44.9%; EPS growth 74.7% vs 46.2%; TTM ROE -12.2% vs 3.4%; gross margin 93.2% vs 93.5%; operating margin -17.7% vs -43.4%
ValuationAXSMValue 65 vs 55
TechnicalsBBIOPrice vs 50-day -17.4% vs 11.9%; vs 200-day -28.1% vs 7.7%
Risk ResilienceBBIORisk Resilience 57 vs 62
Analyst expectationsAXSMTarget upside 83.6% vs 42%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AXSM and BBIO and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is wide at 17 points. (supports the conclusion holding)
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
  • The lead has swung materially session to session. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)
  • Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BBIO.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

BBIO lead: Reversed — AXSM led by 1 AIQ points 30 sessions ago; BBIO now leads by 17.

May 27AXSM leads above the line · BBIO leads belowNov 13
Today
BBIO +17
47 vs 64
7 sessions ago
BBIO +15
47 vs 62
30 sessions ago
AXSM +1
51 vs 50
90 sessions ago
AXSM +2
61 vs 59

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

AXSMConflicted

1 bullish / 2 bearish / 1 neutral, conflicted

Only AXSM

  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.51%)
  • Downtrend Structure Active — bearish, trend, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
BBIOConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only BBIO

  • ADX Trend Strengthening — neutral, trend, medium horizon
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.38x)
  • TRIX Bullish Signal — bullish, momentum, short horizon

Both carry 1 more signal that do not separate them: Death Cross Active.

BBIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

AXSMNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.86%, AIQ 0 points).

BBIOConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.17%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1AXSM closes the Momentum gap — currently 45 points behind, the largest single contributor to BBIO's edge.
  2. 2AXSM's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3BBIO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

Split
MetricAXSMBBIO
Revenue growth (YoY)18.9%44.9%
EPS growth (YoY)74.7%46.2%
Gross margin93.2%93.5%
Operating margin-17.7%-43.4%
Return on equity (TTM)-12.2%3.4%
Debt to equity2.07-1.5

Performance

BBIO leads 5 of 6 windows
MetricAXSMBBIO
1 week (5 sessions)7%5.4%
1 month (20 sessions)-9.8%17.9%
3 months (63 sessions)-34.5%-2%
6 months (126 sessions)-37.8%18.4%
Year to date-22.4%2.4%
1 year (252 sessions)0.6%18.2%

Technicals

BBIO has the stronger structure
MetricAXSMBBIO
RSI (14)40.865
ADX (14)37.238.9
Price vs 50-day-17.4%11.9%
Price vs 200-day-28.1%7.7%
Volatility (1M, annualized)53.2%39.1%

Risk

BBIO is the more resilient
MetricAXSMBBIO
Beta0.660.95
Sharpe ratio0.20.55
Sortino ratio0.340.84
Max drawdown-49.1%-29.8%
Current drawdown-44.5%-13.2%
Annualized volatility45.8%44.1%
Value at risk (95%)-4.1%-4%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, AXSM or BBIO?

On the Algovestiq AIQ Score, BBIO is the stronger of the two as of Nov 15, 2026, scoring 64 against AXSM's 47. The edge comes from momentum and quality. AXSM is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is AXSM or BBIO the better buy right now?

BBIO carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.

Why does the AIQ Score favor BBIO over AXSM?

The composite weights Quality, Value, Momentum and Risk Resilience. BBIO leads Momentum by 45 points; AXSM leads Value by 10 points; BBIO leads Quality by 9 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, AXSM or BBIO?

Analyst price targets imply +83.6% upside for AXSM and +42% for BBIO, so the Street currently favors AXSM. That points the opposite way to the AIQ Score, which favors BBIO. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, AXSM or BBIO?

AXSM is the better-valued of the two on the peer-relative Value factor. AXSM on the peer-relative Value factor, by 10 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, AXSM or BBIO?

AXSM on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, AXSM or BBIO?

BBIO on the Momentum factor, by 45 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, AXSM or BBIO?

BBIO is the more resilient of the two, so the other name carries the higher downside risk. BBIO on Risk Resilience, by 5 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is AXSM more profitable than BBIO?

The profitability evidence is mixed: gross margin 93.2% vs 93.5%; operating margin -17.7% vs -43.4%; ttm roe -12.2% vs 3.4%. Each name leads on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is BBIO's lead over AXSM getting stronger or weaker?

BBIO lead: Reversed — AXSM led by 1 AIQ points 30 sessions ago; BBIO now leads by 17. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the AXSM vs BBIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: AXSM closes the Momentum gap — currently 45 points behind, the largest single contributor to BBIO's edge; AXSM's Death Cross Active resolves — a bearish trend rule currently active against it; BBIO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about AXSM and BBIO?

AXSM: 1 bullish / 2 bearish / 1 neutral, conflicted. BBIO: 2 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AXSM is Death Cross Active (bearish, long horizon). On BBIO it is Death Cross Active (bearish, long horizon).

Compare AXSM and BBIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.